Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Keilholz

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
New prognostic factors in melanoma: mRNA tumour markersU Keilholz
Cancer|February 15, 1995
Chemoimmunotherapy of melanoma. Is it time for phase III trials?U Keilholz
Der Urologe. Ausg. A|May 19, 2004
Immunotherapy in non-renal carcinomasU Keilholz
Seminars in Surgical Oncology|December 18, 2001
Minimal residual disease in melanomaN Max, U Keilholz
Current Pharmaceutical Biotechnology|May 31, 2011
Role of TGF-β in melanomaA Busse, U Keilholz
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
appendix 2: Cutaneous melanoma (2): eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Melanoma)R Dummer, U Keilholz,
The American Journal of the Medical Sciences|April 1, 1986
Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiencyU Keilholz, G P Guthrie
The Cancer Journal From Scientific American|February 24, 2000
The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group programU Keilholz, A M Eggermont
Oncology|March 8, 2000
The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative GroupU Keilholz, A M Eggermont
Journal of Immunological Methods|March 31, 1998
Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral bloodA Schmittel, U Keilholz, C Scheibenbogen
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
New prognostic factors in melanoma: mRNA tumour markersU Keilholz
Cancer|February 15, 1995
Chemoimmunotherapy of melanoma. Is it time for phase III trials?U Keilholz
Der Urologe. Ausg. A|May 19, 2004
Immunotherapy in non-renal carcinomasU Keilholz
Seminars in Surgical Oncology|December 18, 2001
Minimal residual disease in melanomaN Max, U Keilholz
Current Pharmaceutical Biotechnology|May 31, 2011
Role of TGF-β in melanomaA Busse, U Keilholz
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
appendix 2: Cutaneous melanoma (2): eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Melanoma)R Dummer, U Keilholz,
The American Journal of the Medical Sciences|April 1, 1986
Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiencyU Keilholz, G P Guthrie
The Cancer Journal From Scientific American|February 24, 2000
The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group programU Keilholz, A M Eggermont
Oncology|March 8, 2000
The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative GroupU Keilholz, A M Eggermont
Journal of Immunological Methods|March 31, 1998
Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral bloodA Schmittel, U Keilholz, C Scheibenbogen
Pageof 15